A Targeted Approach to laBCC: Innovations in Treatment Options for Locally Advanced Basal Cell Carcinoma

Basal cell carcinoma or BCC is the most common cancer worldwide. But up to 1% of these cancers become locally advanced. Locally advanced basal cell carcinomas or laBCCs are much harder to treat through conventional treatment methods. ODOMZO® (sonidegib) is a prescription medicine used to treat adults with basal cell carcinoma that has come back following surgery or radiation or that cannot be treated with surgery or radiation. ODOMZO is currently the only hedgehog pathway inhibitor (HHI) proven to provide more than 2 years of tumor response in laBCC patients. Watch as Dr. Aaron Farberg and his laBCC patient Kara explore this treatment option.